Search results
New Drugs Won’t Help If They Can’t Reach Patients. My Family Learned the Hard Way.
Barrons.com· 5 days agoChristine Schuster spent her life in healthcare. That wasn’t enough when her husband couldn’t get...
Multilingual education program boosts healthcare workforce in Augusta
WCSH 6 Portland· 4 days agoMaineGeneral Medical Center in Augusta is helping new Mainers get acclimated to the English language...
The People's Pharmacy: Can aspirin prevent colon cancer and strokes?
Richmond Times-Dispatch· 5 days agoQUESTION: My father had colon cancer, and I have had polyps myself, including a precancerous one....
How the Medical Industry Could Produce the Biggest AI Stock Winners
InvestorPlace· 5 days agoEditor’s note: “How the Medical Industry Could Produce the Biggest AI Stock Winners” was previously...
Marijuana reclassification could clear hurdles for NJ businesses
NJBIZ· 6 days agoThe U.S. Drug Enforcement Administration is taking steps to reclassify marijuana as a lower-risk...
Why Britain has failed miserably to solve its potholes crisis – and how to fix it
The Telegraph via Yahoo News· 6 days agoThis is the first in a series of articles, each of which will take an in-depth look at the failing...
Merck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.
Quartz· 3 days agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar...
Great performers constantly rehearse. Companies that want to survive sustained change must do the...
Fortune via Yahoo Finance· 4 days agoDon’t wait until the end of the year. The company needs to continually adjust to what jobs are not...
3 Top Dividend Stocks to Maximize Your Retirement Income
Zacks· 6 days agoFor example, 10-year Treasury bonds in the late 1990s offered a yield of around 6.50%, which translated to an income source you could count on. While this yield reduction ...
The hell of drug pricing boards
Maryland Matters via Yahoo News· 2 days agoJames K. Glassman, the well-known economist whose clients have included pharmaceutical companies, makes the case against prescription drug affordability boards. The post The ...